Patrick Tricoli has become global head of business development at Nanobiotix SA following a corporate reorganisation which also saw Edwina Baskin-Bey become chief medical officer and Elsa Borghi head of drug discovery. Nanobiotix recently received EU approval for a nanoparticle device designed to enhance the effect of radiation in the treatment of soft tissue sarcoma. In addition to his new responsibilities, Dr Tricoli will remain chief executive of the company’s US affiliate Nanobiotix Corp.
Dr Tricoli joined Nanobiotix in 2014. Prior to this, he was an executive at Sanofi SA helping oversee partnering and pharma technology deals with third parties. He holds a Doctor of Pharmacy degree and a Master of Business Administration from ESCP Europe.
Nanobiotix announced the appointment on 1 July 2019.
Copyright 2019 Evernow Publishing Ltd